Innogen M30 (soluble insulin): Uses, Dosage & Side Effects

What it's for (Indications)

Soluble insulin, also known as regular insulin (e.
g.
, Innogen-N), is indicated for the treatment of diabetes mellitus in patients requiring insulin for glycemic control.
This includes both Type 1 diabetes (insulin-dependent diabetes mellitus), where pancreatic beta cells produce little to no insulin, and Type 2 diabetes (non-insulin-dependent diabetes mellitus), where the body either doesn't produce enough insulin or doesn't use insulin effectively.
It is also utilized in the management of diabetic ketoacidosis (DKA) and hyperosmolar hyperglycemic state (HHS), often via intravenous infusion for rapid glucose lowering.
Furthermore, soluble insulin can be used in the emergency treatment of severe hyperkalemia to shift potassium intracellularly, reducing serum potassium levels.

Dosage Information

Type	Guideline
Standard	The dosage of soluble insulin must be highly individualized and determined by a healthcare professional based on the patient's specific metabolic needs, blood glucose levels, lifestyle (e.g., diet, exercise), concomitant medications, and overall clinical status. Soluble insulin is typically administered subcutaneously, 30 to 45 minutes before a meal, but can also be given intravenously in emergency situations such as DKA or severe hyperkalemia under strict medical supervision. Dosing regimens vary widely, ranging from single daily injections to multiple daily injections as part of a basal-bolus regimen. Initial doses are often calculated based on body weight (e.g., 0.3-0.6 units/kg/day, divided), but subsequent adjustments are crucial and guided by frequent blood glucose monitoring. Self-monitoring of blood glucose (SMBG) is essential for patients to adjust insulin doses as advised by their physician, preventing both hyperglycemia and hypoglycemia. Never adjust dosage without consulting a healthcare provider.

Type

Guideline

Standard

The dosage of soluble insulin must be highly individualized and determined by a healthcare professional based on the patient's specific metabolic needs, blood glucose levels, lifestyle (e.g., diet, exercise), concomitant medications, and overall clinical status. Soluble insulin is typically administered subcutaneously, 30 to 45 minutes before a meal, but can also be given intravenously in emergency situations such as DKA or severe hyperkalemia under strict medical supervision. Dosing regimens vary widely, ranging from single daily injections to multiple daily injections as part of a basal-bolus regimen. Initial doses are often calculated based on body weight (e.g., 0.3-0.6 units/kg/day, divided), but subsequent adjustments are crucial and guided by frequent blood glucose monitoring. Self-monitoring of blood glucose (SMBG) is essential for patients to adjust insulin doses as advised by their physician, preventing both hyperglycemia and hypoglycemia. Never adjust dosage without consulting a healthcare provider.

Safety & Warnings

Common Side Effects

The most common and clinically significant side effect associated with soluble insulin therapy is **hypoglycemia**, which can range from mild to severe and life-threatening.
Other common side effects include **injection site reactions** such as pain, redness, itching, swelling, or bruising, which are usually mild and transient.
Long-term subcutaneous injections at the same site can lead to **lipodystrophy** (lipohypertrophy or lipoatrophy), characterized by localized fat accumulation or depression under the skin, which can affect insulin absorption.
Patients may also experience **weight gain** due to improved glucose utilization.
Less common but serious side effects include generalized allergic reactions (e.
g.
, rash, pruritus, bronchospasm, hypotension, anaphylaxis), **hypokalemia** (especially with intravenous administration or in patients predisposed), and **peripheral edema**.

Serious Warnings

Black Box Warning: ### SERIOUS WARNINGS: HYPOGLYCEMIA AND HYPOKALEMIA Soluble insulin, while critical for glycemic management, carries significant risks that necessitate meticulous patient management and education. The most profound and immediate danger associated with insulin therapy is **hypoglycemia**, a state of dangerously low blood glucose levels. Hypoglycemia can occur rapidly and, if severe, can lead to serious neurological impairment, seizures, coma, and even death. Patients and their caregivers must be thoroughly educated on the recognition of hypoglycemic symptoms (e.g., sweating, tremor, hunger, confusion, dizziness, palpitations) and the immediate steps for treatment. Regular and frequent self-monitoring of blood glucose (SMBG) is crucial for preventing and detecting hypoglycemic episodes early. Factors such as changes in meal timing, increased physical activity, concomitant medications, or renal/hepatic impairment can significantly increase the risk of hypoglycemia. Additionally, insulin administration, particularly at high doses or intravenously (e.g., in DKA treatment), can cause a significant shift of potassium from the extracellular to the intracellular space, leading to **hypokalemia**. Severe hypokalemia can manifest as life-threatening cardiac arrhythmias, muscle weakness, respiratory paralysis, or rhabdomyolysis. Patients at risk, such as those with existing renal impairment, diuretic use, or conditions causing potassium loss, require close monitoring of serum potassium levels before and during insulin therapy. Prompt recognition and correction of hypokalemia are essential to prevent severe complications. Careful individualized dosing, patient education, and ongoing clinical surveillance are paramount to mitigate these serious adverse events.
Patients using soluble insulin must be vigilant for and educated about the signs and symptoms of **hypoglycemia**, the most critical acute complication.
Factors increasing hypoglycemia risk include changes in meal patterns, increased physical activity, renal/hepatic impairment, and concomitant medications.
**Hypokalemia** can occur with insulin administration; monitor potassium levels, especially in patients at risk.
**Medication errors**, such as accidental administration of other insulin formulations or incorrect dosing, can lead to serious adverse events.
Insulin needs may change during periods of illness, stress, or with changes in diet or exercise, necessitating close monitoring.
Use with caution in patients with **renal or hepatic impairment**, as insulin clearance may be reduced.
Concurrent use of certain medications (e.
g.
, beta-blockers, ACE inhibitors, diuretics, corticosteroids) can alter insulin requirements or mask hypoglycemia symptoms.
Allergic reactions, though rare, can be severe; patients should be advised on appropriate responses.
Insulin pens or syringes must never be shared between patients due to the risk of blood-borne pathogen transmission.

How it Works (Mechanism of Action)

Soluble insulin, a short-acting human insulin analogue, acts as a primary regulator of glucose metabolism. Its mechanism involves binding to specific insulin receptors on target cells, primarily in the liver, muscle, and adipose tissue. This binding initiates a cascade of intracellular events that promote glucose uptake from the blood into these cells, thus lowering blood glucose levels. In muscle and adipose tissue, insulin facilitates the translocation of glucose transporters (e.g., GLUT4) to the cell membrane, increasing glucose entry. In the liver, insulin inhibits hepatic glucose production (glycogenolysis and gluconeogenesis) and promotes glycogen synthesis (glycogenesis). Additionally, insulin promotes the storage of fat and protein synthesis while inhibiting their breakdown, thereby exerting its anabolic effects. Its rapid onset and relatively short duration of action make it suitable for mealtime coverage and acute glycemic control.